ABBISKO-B(02256): The oral small molecule KRAS G12D inhibitor ABSK141 has obtained IND approval from NMPA.

08:02 24/12/2025

He Yu-B (02256) announced that its subsidiary, Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu Medicine) announced that its oral, highly active, and highly selective small molecule KRAS G12D inhibitor ABSK141 for the treatment of advanced solid tumor patients carrying KRAS G12D mutations has received approval from the China National Medical Products Administration (NMPA) for a new drug clinical trial application (IND).

ABBISKO-B (02256) issued an announcement, the company's subsidiary Shanghai Geneplus Bio-Medical Technology Co., Ltd. (Geneplus Bio-Medical) announced that its orally-administered, high-activity, high-selectivity small molecule KRAS G12D inhibitor ABSK141 for the treatment of patients with advanced solid tumors carrying the KRAS G12D mutation has been approved for new drug clinical trial (IND) application by the National Medical Products Administration (NMPA) of China.

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"